Your browser doesn't support javascript.
loading
A matching-adjusted indirect comparison of combination nivolumab plus ipilimumab with BRAF plus MEK inhibitors for the treatment of BRAF-mutant advanced melanoma☆.
Tarhini, A A; Toor, K; Chan, K; McDermott, D F; Mohr, P; Larkin, J; Hodi, F S; Lee, C-H; Rizzo, J I; Johnson, H; Moshyk, A; Rao, S; Kotapati, S; Atkins, M B.
Afiliação
  • Tarhini AA; Departments of Cutaneous Oncology and Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, USA. Electronic address: Ahmad.Tarhini@moffitt.org.
  • Toor K; Evidence Synthesis and Decision Modeling, Precision HEOR, Vancouver, Canada.
  • Chan K; Evidence Synthesis and Decision Modeling, Precision HEOR, Vancouver, Canada.
  • McDermott DF; Medical Oncology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, USA.
  • Mohr P; Department of Dermatology, Elbe Kliniken Buxtehude, Buxtehude, Germany.
  • Larkin J; Medical Oncology, The Royal Marsden Hospital, London, UK.
  • Hodi FS; Medical Oncology, Dana-Farber/Harvard Cancer Center, Boston, USA.
  • Lee CH; US Health Economics and Outcome Research, Metastatic Melanoma, Bristol Myers Squibb, Princeton, USA.
  • Rizzo JI; Oncology Clinical Development, Bristol Myers Squibb, Princeton, USA.
  • Johnson H; Worldwide Health Economics and Outcomes Research, Melanoma, Bristol Myers Squibb, Uxbridge, UK.
  • Moshyk A; Worldwide Health Economics and Outcomes Research, Melanoma, Bristol Myers Squibb, Princeton, USA.
  • Rao S; US Health Economics and Outcome Research, Metastatic Melanoma, Bristol Myers Squibb, Princeton, USA.
  • Kotapati S; Worldwide Medical, Melanoma, Bristol Myers Squibb, Princeton, USA.
  • Atkins MB; Medical Oncology, Georgetown Lombardi Comprehensive Cancer Center, Washington, DC, USA.
ESMO Open ; 6(2): 100050, 2021 04.
Article em En | MEDLINE | ID: mdl-33556898
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Nivolumabe / Melanoma Tipo de estudo: Clinical_trials / Prognostic_studies / Systematic_reviews Limite: Humans Idioma: En Revista: ESMO Open Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Nivolumabe / Melanoma Tipo de estudo: Clinical_trials / Prognostic_studies / Systematic_reviews Limite: Humans Idioma: En Revista: ESMO Open Ano de publicação: 2021 Tipo de documento: Article